ciglitazone has been researched along with Neoplasms in 2 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Papi, A | 1 |
| Rocchi, P | 1 |
| Ferreri, AM | 1 |
| Guerra, F | 1 |
| Orlandi, M | 1 |
| Marra, F | 1 |
| Pastacaldi, S | 1 |
1 review available for ciglitazone and Neoplasms
| Article | Year |
|---|---|
[Thiazolidinediones and PPARgamma system in repair of liver damage].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antioxidants; Arteriosclerosis; Chro | 2002 |
1 other study available for ciglitazone and Neoplasms
| Article | Year |
|---|---|
Enhanced effects of PPARgamma ligands and RXR selective retinoids in combination to inhibit migration and invasiveness in cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Drug Synergism; Humans; Matrix Metalloprotei | 2009 |